Cronos Group Inc. (CRON)
Cronos Group Inc. (CRON) Q4 2024 Earnings Call Transcript
Cronos Group Inc. (NASDAQ:CRON ) Q4 2024 Results Conference Call February 27, 2025 8:30 AM ET Company Participants Anna Shlimak - Chief Strategy Officer Mike Gorenstein - Chairman, President and Chief Executive Officer James Holm - Chief Financial Officer Operator Good morning. My name is Antoine, and I will be your conference operator today.
Cronos Group (CRON) Reports Q4 Loss, Misses Revenue Estimates
Cronos Group (CRON) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.05 per share a year ago.
Why Cronos Group Stock Popped 9% Today
Cronos stock just went up -- a lot. Maybe it's time to sell?
Cronos Group Inc. (CRON) Q3 2024 Earnings Call Transcript
Cronos Group Inc. (NASDAQ:CRON ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Anna Shlimak - Chief Strategy Officer Mike Gorenstein - Chairman, President and CEO James Holm - CFO Conference Call Participants Matt Bottomley - Canaccord Genuity Bill Kirk - Roth Capital Partners Operator Good morning. My name is Brianna and I will be your conference operator today.
3 Marijuana Stocks To Watch On September 11th
Over the last several days some marijuana stocks have begun to pick up in momentum. There have been several attempts to show good faith in the legalization efforts for cannabis markets across the USA. Recently Trump has shown his support for legal cannabis in Florida under the right conditions. From this news, more people began to speculate that Trump's support can mean big things for legal cannabis. In addition to fueling more profitable trading in the hopes of better reform measures.
Why Cronos Group Stock Is Sinking Today
The DEA scheduled a public meeting about cannabis rescheduling for Dec. 2, 2024. It's possible that cannabis won't be rescheduled before the next president takes office, if at all.
Buy Cronos Stock Before It Surges Higher
Initiating coverage on Cronos stock with a "Strong Buy" rating. Cannabis industry tailwinds, conservative growth approach, and geographic expansion support Cronos' growth acceleration and EBITDA margin improvement. A strong cash buffer of $848 million coupled with a zero-debt balance sheet provides flexibility for organic and acquisition-driven growth.
7 Growth Stocks to Buy on Corrections for 3X Returns by 2026
The S&P 500 index touched highs of 5,670 in July. Over the last one month, the index movement has been volatile with a downward bias.
Why Investors Were High on Cronos Group Today
The Canadian cannabis purveyor saw a leap in revenue for its second quarter. This was largely, but not entirely, due to higher sales in its home market.
7 Growth Stocks That Could 7X in the Next 7 Years
The recent market correction is a reminder to investors that it's important to remain grounded even during bull markets. By this, I imply having a balanced portfolio and staying away from overvalued stocks.
How the head of cannabis company Cronos dealt with a negative report from indicted short seller Andrew Left
Cronos Group's Chief Executive Mike Gorenstein was giving a tour of one of the company's cannabis growing facilities in 2018 when he heard that his company's stock was down sharply.
7 Growth Stocks That Will Outperform the Markets Through 2028
If we look at high-quality growth stocks, the revenue and EBITDA upside is not just for a year or two. Companies continue to grow at a CAGR of 20% to 30% in the long term.
